Boston Scientific restructuring update
This article was originally published in The Gray Sheet
Executive Summary
Sale of Boston Scientific's cardiac surgery and vascular surgery units will be considered as part of the firm's ongoing effort to divest "non-strategic" assets to help cut costs and reduce debt, the company announces Aug. 16. The move comes on top of earlier plans to explore the sale of the firm's Namic fluid management business, announced July 24 (1"The Gray Sheet" July 30, 2007, p. 17), and the recent sale of its cochlear implant business (2"The Gray Sheet" Aug. 13, 2007, p. 11). Boston Scientific recently decided to retain its endosurgery and pain management businesses, however, following a review (3"The Gray Sheet" Aug. 6, 2007, In Brief). Boston Scientific acquired the cardiac surgery unit, which makes minimally invasive heart surgery devices and generates $189 million in annual sales, as part of its April 2006 acquisition of Guidant. The vascular surgery division, which makes aneurysm repair devices and generates sales of $86 million, was acquired with Meadox Medicals in 1995...
You may also be interested in...
Boston Scientific Cuts Workforce By 13% To Help Save In ’08 H
Boston Scientific will reduce its head count by 2,300 and consolidate certain business units as part of a broader restructuring plan aimed at saving an estimated $475 million to $525 million in 2008, the firm announced Oct. 17
Mergers & Acquisitions In Brief
Ecolab's Microtek deal focuses on infection prevention: Acquisition of Microtek Medical for $274 million is intended to expand Ecolab's infection prevention offerings, Ecolab announces Aug. 7. Microtek's surgical drapes, disposable linens, and fluid and medical waste management equipment will dovetail with Ecolab's surface disinfectants, instrument cleaning detergents and surgical hand scrubs. Microtek reported second quarter revenue of $38.5 million, up 6.8%. Ecolab, with Q2 sales of $1.4 billion (up 11%) bills itself as "the world's leading provider of cleaning, food safety and health protection products and services". Ecolab will pay $6.30 in cash for each of Microtek's 43.5 million shares outstanding - representing a 34% premium over Microtek stock's Aug. 7 closing price of $4.69...
Boston Scientific Pursues Cost Cutting, Asset Sales
Boston Scientific plans to cut costs to address the reality that its core implantable defibrillator and drug-eluting stent businesses have not rebounded as predicted at the beginning of the year